🇺🇸 Sodium valporate in United States

15 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

• Window: 28 March 2025 – 28 March 2026
• Total reports: 15

Most-reported reactions

1. Condition Aggravated — 3 reports (20%)
2. Agitation — 2 reports (13.33%)
3. Circulatory Collapse — 2 reports (13.33%)
4. Rhabdomyolysis — 2 reports (13.33%)
5. Acute Hepatic Failure — 1 report (6.67%)
6. Aggression — 1 report (6.67%)
7. Amnesia — 1 report (6.67%)
8. Angioedema — 1 report (6.67%)
9. Anxiety — 1 report (6.67%)
10. Arthralgia — 1 report (6.67%)

Source database →

Frequently asked questions

Is Sodium valporate approved in United States?

Sodium valporate does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for Sodium valporate in United States?

Sanofi is the originator. The local marketing authorisation holder may differ — check the official source linked above.